A six-epithelial-mesenchymal transition gene signature may predict metastasis of triple-negative breast cancer

- Wei, Li Yuan, Zhang, Xiao Jun, Wang, Li, Hu, Li Na, Zhang, Xu Dong, Li, Li, Gao, Jin Nan

Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer

- Scurry, James, van Zyl, Belinda, Gulliver, Damien, Otton, Geoffrey, Jaaback, Kenneth, Lombard, Janine, Vilain, Ricardo E., Bowden, Nicola A.

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer

- Biswas, Tithi, Efird, Jimmy T., Prasad, Shreya, Jindal, Charulata, Walker, Paul R.

Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy

- Leong, Kin Men, Lau, Peter, Ramadan, Saadallah

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

- McCarthy, N., Boyle, F., Gebski, V., Veillard, A. S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., Forbes, J. F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P. A., Chirgwin, J., Abdi, E.